The “Gordian Knot” is a legendary tale of an unbreakable intricate knot, which could never be unraveled until Alexander the Great boldly cut the knot with his sword, fulfilling the legend that he would become the next ruler of Asia. Since then, the Gordian Knot has become a metaphor for impossible to solve medical, political, and mathematical problems. The logo of PridCor Therapeutics, LLC illustrates our commitment to unraveling the “Gordian Knot” that is Long COVID and other instances of post viral syndrome.
Pharmaceutical companies and academic research centers struggle with expensive, time consuming, non-productive, single-agent clinical trials for chronic ailments like fibromyalgia, MECFS, and now Long COVID. They have been unable to unravel the complexities of these post viral illnesses.
PridCor’s research has developed a specialized treatment that addresses the underlying causes of Long COVID. This unique, precise, and revolutionary approach has the strong possibility to not only successfully unravel the mystery of Long COVID, but also other “Gordian knot’ conditions like MECFS, fibromyalgia and IBS.
SARS CoV-2 triggered the worst pandemic in over 100 years. Tragically, for many, this illness produced a post viral syndrome that resulted in dramatic systemic and immune alterations. Latest estimates claim there are approximately 20 million Long COVID sufferers in the US and approximately 400 million Long COVID patients worldwide.
The societal and financial consequences of Long COVID will be enormous with one expert placing the estimate at a staggering $3.7 trillion. This global surge in Long COVID has become the next pandemic. The US government and academia are clearly committed to conquering this illness, as the US government spent roughly $2 billion dollars on the RECOVER Initiative programs and 63 top hospitals have set up new clinics for the sole purpose of treating these unfortunate patients.
PridCor Therapeutics, LLC will be collaborating with world renowned researchers at Mount Sinai Health System in New York in an upcoming groundbreaking Long COVID study, where the remarkable efficacy of this new treatment will be demonstrated.
It is widely known that traditionally, medical researchers like their progress to come in small incremental changes. Said more concisely, science advances one “funeral at a time.” PridCor Therapeutics, LLC sees the “Gordian Knot” as not merely a legend, but an urgent call needed for change. It is a bold new philosophy and guiding principle for future biotech companies to strive for leaping groundbreaking discoveries.
Bringing over three decades of experience in venture capital, strategic leadership, and biotechnology innovation. Known for his ability to identify and cultivate transformative healthcare technologies, Brian has successfully guided numerous biotech ventures from early-stage development through commercialization, leveraging his extensive network within the venture capital community.
As the Chairman and CEO of BullBear Partners, a leading venture capital firm he founded in 2002, Brian has consistently championed investments in groundbreaking biotech and medical device enterprises. His strategic foresight and deep understanding of capital markets have driven significant growth and value creation for his portfolio companies, positioning them as industry leaders.
Prior to establishing BullBear Partners, Brian held executive roles at premier Wall Street firms including Bear Stearns, Prudential Securities, and A.G. Edwards, where he specialized in mergers, acquisitions, capital trading, and funding strategies. His distinguished career is marked by his commitment to building companies founded on integrity, innovation, and sustainable value.
At PridCor Therapeutics, Brian applies his seasoned expertise and investor acumen to advance pioneering treatments and devices, aiming to dramatically improve patient outcomes. His leadership is instrumental in securing robust venture capital support, fueling PridCor’s mission to revolutionize therapeutic solutions for critical medical challenges.
Brian is an alumnus of the University of Georgia and remains actively involved in international affairs, charitable endeavors, and community coaching initiatives, reflecting his dedication to positive impact beyond the business sphere.
Founder & Chief Executive Officer of PridCor Therapeutics
Successfully Founded Virios Therapeutics now trading as Dogwood Therapeutics on the NASDAQ.
With over two decades of clinical expertise as a board-certified surgeon, Dr. Pridgen is widely acclaimed for developing the groundbreaking PridCor Protocol, a novel therapeutic regimen designed specifically to address the complex biological foundations of Long COVID.
Driven by an unwavering commitment to patient care and scientific innovation, Dr. Pridgen uniquely combines extensive real-world clinical experience with pioneering research. His innovative approach has significantly advanced the understanding of chronic viral conditions and has positioned PridCor Therapeutics at the forefront of healthcare innovation.
Dr. Pridgen’s visionary leadership and deep understanding of both clinical practice and pharmaceutical development have earned him recognition as a leading authority in biotechnology-driven healthcare solutions. His relentless dedication to enhancing patient outcomes continues to drive transformative advancements in medicine.
📍 Headquarters: Tuscaloosa, AL
📧 Email: info@pridcor.com
📞 Phone: 205-366-0696
